Skip to main
DXCM

DexCom (DXCM) Stock Forecast & Price Target

DexCom (DXCM) Analyst Ratings

Based on 22 analyst ratings
Buy
Strong Buy 55%
Buy 32%
Hold 9%
Sell 5%
Strong Sell 0%

Bulls say

DexCom is poised for continued growth thanks to the positive results of its CGM systems in both clinical trials and real-world usage. The company has a strong product pipeline and a solid management team, and its innovative technology sets it apart in the market. DexCom's involvement in the T2NIT coverage expansion initiative puts it in a prime position to benefit from the potential adoption of CGM systems in the non-insulin type 2 diabetes population. However, there are potential risks to the diabetes device sector, such as regulatory processes and potential pricing pressures, that investors should consider. Based on the company's recent financial performance and its potential for future growth, a Buy rating is appropriate with a price target of $75.

Bears say

DexCom is facing pricing headwinds in the short and long term due to market dynamics and competition, as well as potential regulatory hurdles that could delay new product releases. However, the company has a strong market position with its top-tier management team and a profitable model, making it a leader in the continuous glucose monitoring market. Risks of low CGM adoption and potential disruptions from competitors exist, but DXCM's robust pipeline provides potential upside for revenue and profit in the future.

DexCom (DXCM) has been analyzed by 22 analysts, with a consensus rating of Buy. 55% of analysts recommend a Strong Buy, 32% recommend Buy, 9% suggest Holding, 5% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of DexCom and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About DexCom (DXCM) Forecast

Analysts have given DexCom (DXCM) a Buy based on their latest research and market trends.

According to 22 analysts, DexCom (DXCM) has a Buy consensus rating as of Aug 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $87.05, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $87.05, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

DexCom (DXCM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.